一名澳大利亚男子在击败高风险前列腺癌后 将临床试验归功于救命的临床试验。 An Australian man credits a clinical trial with saving his life after beating high-risk prostate cancer.

澳大利亚75岁男子Will Creivey表示, 参与ENZARAD审判在2017年被诊断患有高风险前列腺癌后, 帮助挽救了他的生命。 Will Creevey, a 75-year-old Australian man, says participation in the ENZARAD trial helped save his life after being diagnosed with high-risk prostate cancer in 2017. 在高水平的PSA 和生物检查后, 他加入了一项国际研究测试 enzalutamide, 这是第二代抗阳性剂, 对患有非转移性疾病的男性进行。 After an elevated PSA and biopsy revealed aggressive cancer, he joined an international study testing enzalutamide, a second-generation anti-androgen, in men with non-metastatic disease. 在接受辐射和药物治疗两年后,他的PSA从11降到0.13,他仍然没有癌症。 Under treatment with radiation and the drug for two years, his PSA dropped from 11 to 0.13, and he remains cancer-free. 这次审判由ANZUP领导,涉及来自杭特地区的大约70名男子。 审判发现,这一疗法可能使极有可能再次发生的小群体受益。 The trial, led by ANZUP and involving about 70 men from the Hunter Region, found the therapy may benefit a small group at highest risk of recurrence. 克里维敦促男子按期进行年度体检,并与医生讨论PSA测试,指出他在诊断前一年没有进行血检。 Creevey urges men to stay on schedule with annual check-ups and discuss PSA testing with their doctors, noting he missed a blood test the year before diagnosis.